Showing results (181-190 of 216) with videos related to
Sort By:
Pageof 22
Therapeutic Advances in Medical Oncology|October 26, 2023
Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitorLi-Na He, Tao Chen, Sha Fu, et al.Cancer Medicine|February 12, 2019
Docosapentaenoic acid and lung cancer risk: A Mendelian randomization studyJiaqing Liu, Huaqiang Zhou, Yaxiong Zhang, et al.Plos One|February 18, 2014
Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutationsWenhua Liang, Xuan Wu, Wenfeng Fang, et al.Cellular & Molecular Immunology|December 7, 2023
The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activationFan Luo, Han Li, Wenjuan Ma, et al.Elife|February 28, 2016
Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolismHongyun Zhao, Lifeng Yang, Joelle Baddour, et al.Journal of Cancer|August 19, 2017
The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancerYaxiong Zhang, Gang Chen, Xi Chen, et al.Journal of Translational Medicine|June 4, 2025
HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non-small cell lung cancerJianhua Zhan, Jinhui Xue, Lin Wu, et al.The Oncologist|January 14, 2018
Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-AnalysisZhonghan Zhang, Yaxiong Zhang, Gang Chen, et al.Iscience|July 7, 2023
Machine learning-based risk model incorporating tumor immune and stromal contexture predicts cancer prognosis and immunotherapy efficacyLi-Na He, Haifeng Li, Wei Du, et al.Oncotarget|March 3, 2016
Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network meta-analysisYaxiong Zhang, Jin Sheng, Yunpeng Yang, et al.Pageof 22